###### Strengths and limitations of this study

-   This feasibility study is the first effort to prove that randomising patients to different access strategies is feasible and safe, which is a vital first step to conducting the first randomised controlled trial in this area.

-   This feasibility study has the same design as the hard outcome trial (including the data collection for the primary and secondary outcomes of the hard outcome trial); if the pilot is successful participants will be rolled from the pilot into the larger trial.

-   The questions addressed in this pilot and the hard outcome trial that will follow if the pilot is feasible have been ranked among the top 10 research priorities in dialysis by patients and healthcare providers.

-   The question is asked in people over 65 years of age; results will need to be interpreted and generalised accordingly; the question is asked following haemodialysis start with a catheter (as opposed to the predialysis setting); predialysis education about vascular access may affect the feasibility of this trial.

-   Owing to the nature of the intervention, the study is blinded for the outcome assessors only.

Background {#s1}
==========

Worldwide, over 2 million people receive haemodialysis therapy for end-stage kidney failure.[@R1] These people require access to the bloodstream by means of a fistula or a catheter (the most common forms of vascular access) to connect to the blood purification machine. Guidelines recommend a fistula for haemodialysis access based on evidence from large observational studies showing that fistula use is associated with better clinical outcomes (including mortality) and lower costs than catheter use.[@R4] [@R5] However, there has never been a randomised controlled trial (RCT) comparing fistulas with catheters, and existing studies addressing this question are at high risk of bias, especially selection bias.[@R6] The choice of haemodialysis access is a common intervention question in clinical practice and is very relevant for patients and health policymakers because it impacts morbidity, mortality, quality of life and health costs.[@R11]

In Canada, more than 80% of people with kidney failure who start haemodialysis use a catheter for vascular access, and are faced with the decision to either continue with a catheter or attempt fistula creation.[@R14] [@R15] Although fistula creation is recommended regardless of age,[@R16] promoting fistulas in the elderly may be ineffective as in this patient population fistulas are less likely to become suitable for haemodialysis than in younger people.[@R17] In addition, even when fistula attempts are successful, elderly people may not receive the same benefit as younger people due to their shorter life expectancy. Finally, recent data suggest that the risks associated with catheters (eg, catheter-related bacteraemia) may be lower in the elderly[@R18] and that a person\'s preference for the type of vascular access varies by age, with the elderly being more likely to prefer catheters to fistulas.[@R19] For these reasons, the expected benefits of fistula creation are even more uncertain in the elderly.

A large RCT to determine the benefits and harms of one form of vascular over the other may not be feasible for several reasons. First, people may develop strong preferences for a particular form of vascular access based on the information presented during education about their options. Fistulas require a surgical intervention that can disfigure the arm and require the insertion of needles for dialysis at each treatment (ie, three times per week). Catheters impose lifestyle restrictions (eg, avoidance of swimming) and are visible over the chest. As a consequence, patients may develop strong preferences and be less willing to consent to randomisation. Second, physicians may not be willing to enrol people into a trial due to guideline recommendations and/or existing incentives to increase the number of people treated with fistulas. Third, programmes may not be able to arrange for a fistula creation within a reasonable time (eg, 90 days from randomisation), thereby increasing the risk that consent is withdrawn before the fistula is created or longer exposure to catheters may outdo potential benefits of fistulas. These considerations motivated the design of the present pilot RCT to test the feasibility of a larger, hard outcome trial.

Methods/design {#s2}
==============

Objective and outcomes {#s2a}
----------------------

This pilot RCT will test the feasibility and safety of randomising elderly people who start haemodialysis with a catheter to continued use of a catheter or attempt at fistula creation.

Design {#s2b}
------

This feasibility RCT will be multicentre, parallel-arm and open-label in design. The report of the study protocol conforms to the Standard Protocol Items: Recommendations for Interventional Trials (see online [Supplementary material file](#SM1){ref-type="supplementary-material"}).[@R20] The study process is illustrated in [figure 1](#BMJOPEN2016013081F1){ref-type="fig"}. We will randomise 100 elderly people (age ≥65) with end-stage kidney failure starting haemodialysis with a catheter in 10 Canadian haemodialysis programmes (1:1) to continued use of catheters (comparator) or receive an attempt at fistula creation (intervention). The pilot RCT will consist of 6 months of site preparation, ∼24 months of participant accrual and 6 months of additional follow-up time for the last randomised participant. An additional 6 months will be used to assess the preliminary data, prepare the report of this pilot RCT and to prepare and submit funding applications for a larger hard outcome RCT. Participants in the pilot RCT will be rolled into the hard outcome RCT, and will be followed for a total of 36 months (3 years) after randomisation ([box 1](#bx1){ref-type="boxed-text"}). Box 1Research question (PICOT format)*Question*: Is it feasible to randomly allocate people over 65 who start haemodialysis with a catheter to either continued use of catheter or attempt fistula creation?*Population*: people over the age of 65 who started haemodialysis with a catheter and are eligible for a fistula*Intervention*: attempt at fistula creation*Comparator*: continue with the use of catheters for haemodialysis*Outcomes*: feasibility (randomisation of at least 1 in 4 eligible participants; fistula attempted within 3 months of allocation in at least 3 out of 4 participants assigned to the intervention arm)*Time*: Consent must be obtained within 4 months of haemodialysis start; randomisation must occur within 14 days of attaining participant consent; participants are followed for 6 months since randomisation in this pilot study and then rolled into the hard outcome trial.

![Flow diagram.](bmjopen2016013081f01){#BMJOPEN2016013081F1}

10.1136/bmjopen-2016-013081.supp1

Preliminary data {#s2c}
----------------

Historical data collected as part of quality improvement efforts[@R21] indicate that ∼500 new people start dialysis each year at four of the participating sites (Southern Alberta Renal Program, Calgary; The Ottawa Hospital, Ottawa; St Joseph\'s Health Centre, Hamilton; Sunnybrook Health Sciences Centre, Toronto). Of these people, ∼80% start on haemodialysis (N=400) and 80% of those people use a catheter for haemodialysis access (N=320). According to the same data, at least 50% (N=160) meet the inclusion criteria and if we conservatively assume that 25% of them will consent to randomisation, at least 80 participants will be recruited over 2 years across these four sites. An additional 20 participants will be recruited among the other six participating Canadian centres. The 100-person sample size is reasonable to address the feasibility question of the pilot RCT (ie, whether randomising people to different access strategies is possible). However, identifying barriers to enrolment and thereby, understanding how to maximise enrolment rate at all participating centres will be critical to maximise recruitment rate in the hard outcome RCT. We will continue to monitor these feasibility indicators as the pilot ACCESS HD transitions into the hard outcome ACCESS HD trial.

Participants {#s2d}
------------

We plan to enrol 100 people in total across 10 centres in Canada. This will be possible within 2 years if we enrol 25% of eligible people. We will screen all people who start haemodialysis with a catheter for inclusion in our trial, including people who start haemodialysis in hospital and those who start haemodialysis urgently. We will assess eligibility of these people once they are sufficiently stable to provide informed consent (see the Eligibility criteria section). We will also include people who start as outpatients and those previously treated with haemodialysis therapy before they changed modality to peritoneal dialysis or transplantation. However, only participants with one previous unsuccessful fistula attempt (randomisation will be stratified on this variable) will be eligible. In each centre, we have implemented strategies to identify all new haemodialysis starts within the programme and ensure adequate enrolment to reach the target sample size. We will assess eligibility of all people starting haemodialysis with a catheter and track the time of this assessment relative to the dialysis start date.

Adherence and attrition {#s2e}
-----------------------

One of the objectives of this feasibility RCT is to measure adherence (ie, arranging for a fistula creation within 90 days of randomisation in those assigned to the fistula arm) to demonstrate that centres will adhere to the trial protocol. We will monitor compliance with follow-up visits and the completion of trial questionnaires. We currently track all incident haemodialysis patients at several Canadian sites using a high-quality, web-based platform for the purpose of quality improvement (Dialysis Measurement, Analysis and Reporting (DMAR) System).[@R21] Analysis of two representative programmes suggests that 5% of people starting dialysis transfer out of a dialysis programme or are lost to follow-up over the first year of dialysis.

Eligibility criteria {#s2f}
--------------------

[Table 1](#BMJOPEN2016013081TB1){ref-type="table"} summarises inclusion and exclusion criteria. There are no well-accepted criteria to determine eligibility for a fistula attempt,[@R22] so we will take a pragmatic approach. The team will be free to order any additional investigations required to determine eligibility (eg, vascular mapping), as per local practice. We will collect detailed data around the assessment process at each site during assessment of site feasibility. The determination of eligibility will be the consensus opinion of the primary nephrologist, access surgeon and access nurse (more often based on a series of independent assessments). Only after all assessments and required investigations are completed, will participants be eligible for randomisation.

###### 

Eligibility criteria

  Inclusion criteria                                                                                                                Exclusion criteria
  --------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------
  1\. Adult patients age ≥65                                                                                                        1\. Started haemodialysis with a fistula or have a patent fistula already in place
  2\. Started haemodialysis using a tunnelled, or non-tunnelled catheter for vascular access                                        2\. More than one unsuccessful fistula attempt prior to starting dialysis
  3\. Treated with dialysis for 120 days or less at the time of consent (134 days or less at the time of randomisation)             3\. Has had a prior arteriovenous graft creation
  4\. Clinically stable as assessed by the treating nephrologist (able to provide consent within 120 days of haemodialysis start)   4\. Imminent transplant planned (within 6 months, must be booked)
  5\. Haemodialysis is the intended long-term modality of treatment                                                                 5\. Metastatic malignancies or other condition associated with a life expectancy of \<6 months, in the opinion of the attending nephrologist
  6\. End-stage (permanent) kidney failure unlikely to recover kidney function according to the attending nephrologist              
  7\. Eligible for a fistula attempt as determined by the local multidisciplinary access team                                       
  8\. Planning to remain in the current dialysis centre for at least 6 months                                                       

Participant identification and randomisation {#s2g}
--------------------------------------------

### Participant identification {#s2g1}

The trial coordinator at each site will track people who start haemodialysis and are 65 years of age or older. The coordinator will contact the primary nephrologist of potentially eligible participants to introduce the topic of the trial and advise the patient that the trial team will approach them to discuss participation in the trial. After written informed consent is obtained, the trial coordinator will confirm trial eligibility. All screened people and reasons for exclusion will be documented in a screening log and a minimal data set in the electronic case report form (eCRF) will be collected for all eligible patients including those who do not consent.

### Randomisation and blinding {#s2g2}

Participants will be allocated equally (1:1) to either a fistula attempt (intervention) or continued use of a tunnelled catheter (comparator), stratified by centre and whether or not they have had a prior, unsuccessful fistula attempt. Stratification by these variables will protect randomisation in case the eligibility criteria change for the hard outcome RCT. An independent statistician at the coordinating centre will generate the allocation sequences and keep them concealed from the clinical investigators. Each randomisation list will be generated using randomly permuted blocks of varying sizes. Since this is an open-label trial, knowledge of block sizes could, under certain situations, permit determination of future allocations. For this reason, block size will remain concealed throughout the trial. Randomisation will be operationalised using a web-based, central system (Medidata RAVE). After confirming participant eligibility and obtaining signed consent, the local trial coordinator will obtain the participant\'s assignment electronically via Medidata RAVE. We will not blind participants or providers because the creation of fistulas requires a surgical procedure in the arm, results in clearly visible changes to the appearance of the arm and requires needling of the access for dialysis (as opposed to hub connections). However, outcome adjudicators will be blinded for all outcomes of the larger RCT.

Trial treatments and cointerventions {#s2h}
------------------------------------

### Intervention arm {#s2h1}

Participants will undergo an attempt at fistula creation by an experienced surgeon. Preoperative studies (angiography and/or ultrasound mapping) will be allowed as dictated by indications, local practice and physician preferences. We will collect information about policies and practices, including, for example, the approach to selection of the location of the anastomosis from distal locations (radio-cephalic fistula first) to more proximal locations (brachio-cephalic fistula next and brachio-basilic anastomosis as last choice). Variants on these types of fistulas as well as other options for fistula creation will be at the discretion of the local vascular access team, as per usual practice. The protocol requires that the first fistula attempt occurs within 90 days of randomisation and this pilot RCT will measure adherence to this requirement as a measure of feasibility. In the event that the fistula attempt fails or a functioning fistula experiences a complication that renders it unusable for haemodialysis, further fistula attempts will be at the discretion of the vascular access team and participant; the participant will remain in the intervention arm and 'analysed as randomised' in the definite trial (intention-to-treat).

### Comparator arm {#s2h2}

Participants randomised to the comparator arm will continue to use a tunnelled, central venous haemodialysis catheter for vascular access. Participant using a temporary, non-tunnelled catheter at the time of randomisation will undergo insertion of a tunnelled catheter as per local practice. In the event that the catheter fails or a complication occurs that renders it unusable for haemodialysis, further catheter procedures or fistula attempts will be at the discretion of the vascular access team and participant; the participant will remain in the comparator arm and 'analysed as randomised' in the definite trial (intention-to-treat).

### Cotreatments and access monitoring {#s2h3}

All other aspects of general dialysis care will be dictated by local practice and will not be influenced by the trial protocol.

Outcomes {#s2i}
--------

The primary outcome of this pilot RCT is feasibility. There will be two main determinants of feasibility: our ability to recruit participants and protocol adherence. We will determine the proportion of people meeting our inclusion and exclusion criteria who ultimately consent to randomisation. We aim to consent ≥25% of people who are eligible to be randomised. We will measure protocol adherence based on the ability of the sites to arrange a fistula attempt within 90 days of randomisation to the intervention arm (fistula strategy). We aim to attain a fistula attempt within 90 days of randomisation in ≥80% of participants randomised to the fistula strategy. Other outcomes are reported in [box 2](#bx2){ref-type="boxed-text"}. Box 2Other outcomes1. Feasibility-related outcomes: reasons for exclusion or delayed surgerya. Exclusion of screened people (including competing studies)b. People declining to participatec. People considered ineligible for a fistula attemptd. Delayed access to fistula surgery (\>90 days from randomisation)2. Safety outcomes (to be analysed in the hard outcome RCT)a. Expected procedure-related events ([table 2](#BMJOPEN2016013081TB2){ref-type="table"})b. Hospital admissions or prolongation of hospitalisationc. Death potentially related to the trial procedures3. Other data (to be analysed in the hard outcome RCT)a. Number and reasons for drop-ins (protocol violations)b. Number and reasons for drop-outs (protocol violations)c. Patient-reported outcome measures (PROMs, Quality of life and access questionnaire)d. Physical function (grip strength)e. Fistula data (for intervention arm)f. Resource use

###### 

Expected procedure-related events

  Fistula strategy                                                                          
  ----------------------------------------------------------------------------------------- ------------------------------------------------------------
  Allergic reaction (to local anaesthetic)                                                  Ischaemia (to nerves or distal extremity) or steal
  Allergic reaction (to general anaesthetic)                                                Syndrome requiring intervention
  Bleeding from access site requiring intervention                                          Heart failure (high output congestive)
  Wound infection in the fistula                                                            Nerve injury
  Infection in the bloodstream                                                              Pulmonary embolism
  Excessive collateral formation on upper arm and chest likely from central vein stenosis   Excessive arm swelling likely from central venous stenosis
  Aneurysm requiring intervention                                                           
  Catheter strategy                                                                         
  Allergic reaction (to local anaesthetic)                                                  Catheter malposition
  Allergic reaction (to general anaesthetic)                                                Catheter migration
  Bleeding from access site requiring intervention                                          Catheter embolisation
  Fibrin sheath formation/use of rTPA                                                       Thoracic duct injury
  Infection (exit site)                                                                     Nerve injury
  Infection (tunnel)                                                                        Air embolism
  Infection (bloodstream)                                                                   Venous thrombosis
  Arterial puncture                                                                         Pulmonary embolism
  Myocardial perforation                                                                    Pneumothorax
  Arrhythmias                                                                               Haemothorax

Data collection (eCRF) {#s2j}
----------------------

We will use Medidata RAVE web-based electronic data capture system for randomisation and electronic data capture.

Trial oversight {#s2k}
---------------

The Applied Health Research Centre (AHRC) at St Michael\'s Hospital (Toronto, Canada) will act as the trial coordination and data management centre. Trial coordinators or investigators at each centre will determine eligibility, obtain consent for participation in the trial and utilise the online randomisation tool to allocate participants to the appropriate trial intervention. Trial coordinators will complete the web-based eCRF for each participant. All data will be stored on secure internal servers at St Michael\'s Hospital in Toronto, Ontario. The principal investigators (RQ and PR), in collaboration with the AHRC, will be responsible for trial coordination. The steering committee will include Drs RQ, PR, Barrett, Thorpe, Hiremath, Oliver and Walsh, and will meet before enrolment begins, conduct monthly teleconferences with the AHRC project manager to discuss enrolment rates and operational issues, and again at the end of the trial. The trial protocol received institutional research ethics board (REB) approval in Calgary from the Conjoint Health Research Ethics Board. Approval is currently being sought at all participating sites. All screened people who meet the eligibility criteria will have demographics and clinical characteristics collected in a minimal data set within Medidata RAVE. Every consented participant will have baseline and follow-up data collected as summarised in [figure 2](#BMJOPEN2016013081F2){ref-type="fig"} and in the protocol (see online [Supplementary material file](#SM1){ref-type="supplementary-material"}). Follow-up will start at the time of randomisation in both arms and will continue for 36 months, as participants from this pilot RCT will roll into the hard outcome RCT.

![Schedule of enrolment, interventions and assessment.](bmjopen2016013081f02){#BMJOPEN2016013081F2}

Data safety and monitoring board and end point adjudication committee {#s2l}
---------------------------------------------------------------------

An independent Data Safety and Monitoring Board (DSMB) was formed for the hard outcome RCT. The DSMB will not review the pilot data, but will be responsible for periodic evaluation of the clinical trial data to ensure continued trial participant safety, as well as the scientific validity of the trial. The DSMB met prior to finalising the pilot RCT protocol to draft a functional DSMB charter in preparation for the large RCT. All incidents of participant death that occur during the trial period will be reported.

Protocol violations {#s2m}
-------------------

Protocol violations are reported in [box 3](#bx3){ref-type="boxed-text"}. Box 3Protocol violations1. Failure to attempt the fistula within 90 days of randomisation2. Drop-ins (for reasons of safety, or as requested by the participant; will remain in the trial)Participants randomised to fistula arm1. A fistula is not usable, even after salvage procedures and several attempts2. The fistula is usable but complication rate is high (causing dysfunction or high flow)3. The fistula is usable but needling is not toleratedParticipants randomised to catheter arm1. A working catheter is not achievable, even after several attempts2. The catheter is functioning but complication rate is high3. The catheter is functioning but not accepted4. Drop-outs and their causes (eg, withdrawal of consent or transfer to another centre)

Statistical considerations {#s2n}
--------------------------

### Power and sample size {#s2n1}

The sample size for the feasibility RCT is 100 participants. This number is based on an estimated 25% acceptance rate and a total of 1000 people expected to start haemodialysis in the participating centres over 2 years. Of these, 80% will start with a catheter and 50% are expected to meet the inclusion criteria (conservative number of potentially eligible people N=400). The primary indicators of feasibility will be the proportion of people who are randomised among those who are eligible, and the proportion of fistula attempts that occur within 90 days of randomisation. The pilot RCT will support feasibility if these proportions are at least 25% (100/400 total people) and 80% (40/50 participants assigned to the intervention arm), respectively. Considering the small size of the feasibility RCT and the resulting uncertainty around each estimate (eg, for the second estimate 95% confidence limits range from 9% to 97%), we will continue to monitor feasibility end points after the completion of the pilot RCT and until 100 participants are assigned to the fistula arm in the hard outcome RCT.

### Analysis plan {#s2n2}

The primary analysis will be descriptive. The proportion of people meeting each of the feasibility end points (proportion of people meeting inclusion/exclusion criteria who consent to randomisation; proportion of participants randomised to fistula arm who attempt a fistula creation within 90 days of randomisation) with accompanying 95% CIs will be calculated. We will describe participant characteristics and evaluate reasons for protocol violations. We will calculate rates of drop-ins and other events, although we expect low numbers. We will not conduct any interim or subgroup analyses in this pilot RCT.

Safety data {#s3}
===========

Expected procedure-related events and other outcomes {#s3a}
----------------------------------------------------

As catheter and fistula treatment strategies are standard of care in this patient population, the procedure-related outcomes are well known. We will collect only expected procedure-related events (ie, events that have a potentially causal relationship to the strategy) that occur within 7 days of the execution of any access-related intervention, as listed in [table 2](#BMJOPEN2016013081TB2){ref-type="table"}. In addition, trial coordinators will track causes for hospitalisation to identify outcomes (eg, new-onset peripheral neuropathy or severe sepsis) that may have resulted from the trial procedures ([](#bx2){ref-type="boxed-text"}box 2). Cause of death will be determined by trial site investigators, based on a trial-specific list of classifications, and will be adjudicated for accuracy by appropriate members of the trial steering committee, who will be blind to treatment arm.

Discussion {#s4}
==========

An RCT comparing the effects of catheters and fistulas (the most common types of haemodialysis access being used by \>90% of patients) on clinical outcomes has never been performed. As a result, clinical decision-making in this area is only informed by observational studies, which are not suitable to address intervention questions due to the potential for bias. For example, data from these observational studies indicate that fistulas are superior to catheters in terms of morbidity and mortality outcomes, and healthcare costs. However, these studies compared outcomes of fistula users (typically including only people who could attain a functioning fistula) versus catheter users, including those who were not eligible to receive a fistula, those in whom a fistula was attempted but did not become usable and those who needed an access immediately available for urgent haemodialysis (fistulas require time to mature), and therefore had poorer prognosis.[@R6] As a result, observational evidence indicates superior outcomes in fistula users, but does not demonstrate superiority of an access strategy based on fistulas over an access strategy based on catheters.

The questions addressed in this pilot and the hard outcome trial have been ranked among the top research priorities in dialysis by patients and healthcare providers.[@R13] The nephrology community is increasingly aware of the limitations of available evidence.[@R23] Nevertheless, clinical practice guidelines recommend the fistula as the ideal haemodialysis access, patient advocacy groups strongly promote fistulas over catheters and the proportion of prevalent patients using a fistula is used as a quality of care measure in some jurisdictions.[@R7] Given the uncertainty regarding the willingness of patients and physicians to participate in an RCT in this area, a pilot RCT is necessary to prove the feasibility of a larger study.

Strengths in the design of our feasibility trial include: carefully defined feasibility objectives, clinically grounded, pragmatic approaches to enrolment (eligibility for a fistula) and to delivery of the assigned treatment (access strategy), methods to reduce bias (allocation concealment, objective outcomes, steps to ensure complete follow-up and blinding of outcome adjudicators to treatment assignment), identification of large centres with expertise in vascular access research and care and a coordinating centre with expertise in the management of large multicentre RCTs. These steps will reliably inform the design of the hard outcome trial. In addition, we have included protocols for collection of data that will be analysed in the larger study if this pilot supports feasibility (Patient-Reported Outcome Measures, vascular access questionnaire and physical function as measured by grip strength).

The design of this feasibility RCT has limitations. First, the inclusion criterion of age ≥65 may limit the ability to generalise the findings to younger people who may prefer a fistula to a catheter, and in whom outcomes may differ. However, this criterion is also expected to maximise the chances of success of the pilot RCT by enhancing feasibility, and can be used to inform future studies in younger populations. Second, in the ACCESS HD trial, the question about which access strategy is best for the patient is asked after haemodialysis has started and therefore, focuses on maintaining the strategy in place (the catheter) versus changing strategy (to a fistula). Findings may not be easily generalisable to patients in whom the choice of the access is made prior to the start of haemodialysis (about 20% of people start haemodialysis with a fistula in Canada).[@R14] [@R15] This design has been chosen to enhance study feasibility by limiting the impact of competing events (mortality before end-stage kidney failure or unanticipated availability of a kidney transplant from a living donor), the possibility of changing decision about final dialysis modality or recovery of kidney function with postponement of dialysis initiation and vascular access preparation. Third, it is possible that attending nephrologists and other healthcare providers will have firm beliefs on the potential benefits of fistulas in the haemodialysis population and decline to allow their patients to be enrolled. However, a recent survey including Canadian nephrologists found that the large majority (86%) believed that it would be ethical to randomise elderly patients into such a trial.[@R23]

The type of vascular access used for haemodialysis may have a tremendous impact on the quality and quantity of life of people receiving haemodialysis therapy. The superiority of fistulas over catheters for haemodialysis access has never been demonstrated in a randomised controlled trial, representing an important knowledge gap and research priority. The ACCESS HD pilot RCT is a vital first step to filling this critical knowledge gap and better informing practice as it will establish protocol feasibility and confirm the safety of randomly assigning patients to a catheter-based or a fistula-based strategy for haemodialysis access.

TRIAL STATUS {#s5}
============

Registration information NCT02675569, Recruiting.
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